FRONTEO, Inc.

FRONTEO's original business was legal tech AI. At the time, when Japanese companies faced litigation overseas, no Japanese firm existed to support them, leaving them dependent on foreign providers. Litigation turns on evidence, and that evidence sits within vast volumes of text such as Japanese-language emails and documents. Identifying the correct evidence in Japanese within a short timeframe was technically difficult, and there was a real risk of submitting the wrong material as evidence. The direct motivation for founding the company was the conviction that litigation — which should be conducted under the principle of "equality before the law" — must not be rendered unequal by technical constraints.

This philosophy remains unchanged even as the business footprint has broadened. In the Life Science AI business, the company's current growth area, management views situations where whether dementia or psychiatric disorders are properly diagnosed depends on a physician's experience and ability or on where a patient lives — as well as cases where drugs for intractable and rare diseases go undeveloped due to development cost — as examples of healthcare that should be equal but is not. Transforming the various unfair conditions of the information society into a fair world through AI technology is positioned as the company's highest-order purpose.

Many of the company's employees carry a sense of mission in their respective fields. In legal tech, this applies to litigation and criminal investigation; in drug discovery, to the discovery process itself. Having experienced research stagnation in the absence of breakthrough technology, these are people who want to use AI to solve problems "for companies" and "for patients."

Management expects that five to ten years from now, further globalization will create an increasingly intricate web — spreading like capillaries — and heighten opacity and uncertainty. As a result, the world will broadly split in two: one driven by "correlation," where the majority simply follows the crowd, and another driven by "causation," where causes produce effects. The former is precisely the domain in which generative AI excels. FRONTEO is focusing on the latter and intends to provide AI that discovers causal relationships.

For example, disease does not occur "because everyone gets it" but arises from causes; likewise, the search for criminal evidence and the network visualization of supply chains in economic security are both grounded in causation. That said, the two domains do not separate cleanly, and the company aims to build a unique position as a player that can also correctly identify causal relationships.

Scale Of The Core Battleground

The company views science as its most promising market. In drug discovery, for instance, management estimates that only about 5% of the field has been researched, with the remaining 95% unexplored. These unexplored areas remain untouched because of human preconceptions — they cannot be found within the dynamics of group psychology. Management views the addressable market for its growth areas as extending to the full market size of the pharmaceutical industry.

Differentiated AI Approach

Whereas generative AI and robotics are focused primarily on operational improvement and efficiency, FRONTEO pursues efficiency gains while also leveraging human insight and tacit knowledge to achieve non-linear discovery and push into unexplored territory.

Expansion Into Adjacent Markets

Near-term priorities are two areas: the Life Science AI business covering drug discovery and medical devices, and economic security. Management intends to grow both. Once that growth trajectory becomes visible, candidate areas for the next phase include materials — a Japanese strength (semiconductor materials and the search for substitutes, new construction materials) — plus food and cosmetics, and energy efficiency. The plan is to scale existing businesses first and then move into the next domain, with management recognizing that business expansion will entail capital raising.

Technology Built On A Proprietary Equation

Management identifies technology as its overwhelming competitive advantage today, specifically its proprietary equation-driven AI — AI defined by "what actually drives it." Management believes this equation cannot be replicated by competitors.

Applicability In The Science Domain

Generative AI can only output from "information everyone already knows" and therefore cannot be used in science, where entirely new discoveries that no one yet knows are required. Management believes its technology is the only one capable of identifying causation and delivering new, non-linear discoveries.

Accumulating Track Record

A track record is finally emerging, and management sees the combination of proprietary technology and proven results as the foundation of its future competitive advantage.

Management acknowledges that the current growth rate, even in life sciences, remains in the 30–50% range. Going forward, establishing the brand and delivering US project wins and out-licensing deals should enable 100% growth.

The two most important initiatives toward that goal are establishing brand positioning as a company of national strategic importance in Japan, and winning a large-scale project in the US. Management explains that, while consistently securing projects in Japan is the baseline assumption, these two items are the current top priorities.

The Life Science AI business is currently growing at only around 30–50%. Going forward, establishing the brand and delivering US project wins and out-licensing deals should enable non-linear growth. The two most important initiatives toward that goal are establishing brand positioning as a company of national strategic importance in Japan, and winning a large-scale project in the US.

ROE / ROIC Targets: Not currently used as management metrics; management notes only that it may consider them in the future.

Management identifies the worst-case scenario as an outflow of engineers. Because technology is the source of competitive advantage, talent attrition is positioned as the single largest risk factor.

A second risk is that achievement of the stated KPIs (deployments, out-licensing, US project wins) falls materially behind schedule, leaving the company unable to establish competitive advantage and resulting in significant stagnation.

As a safety net, management points to having two growth areas — the Life Science AI business and economic security. The probability of both failing simultaneously is low, and one can compensate for the other. At present, management sees no significant divergence between its forward outlook and current on-the-ground momentum.

Executive Compensation Structure

The current structure is performance-linked, providing a mechanism that motivates toward results. Share-based compensation has to date been handled through stock options and similar instruments; management intends to examine the optimal approach going forward.

Succession Planning

Management positions executive development as a key priority and continuously considers and executes both internal promotion and external hiring. Regular meetings with outside directors are scheduled, providing management education through dialogue. As a company pursuing growth through new businesses, management believes it is essential to venture into new fields, control risk, and drive growth. Developing and recruiting people who can balance sales, technology, finance and legal perspectives in execution is viewed as critical.

Social (S): Management regards the business itself as ESG, with business growth translating directly into social contribution. The founding purpose of using AI to make unfair conditions in the information society fair is embodied in evidence discovery in litigation, diagnostic support that does not depend on physician experience, and drug discovery for intractable and rare diseases.

Environment (E)

While energy efficiency and the search for new materials are cited as candidate future areas, there is currently no mention of any specific priority theme in the environmental domain.

Governance (G)

Regular meetings with outside directors provide dialogue with management. Details are as described in "Governance and Execution Structure."

Management notes that full retention is difficult in today's environment of increased labor mobility, but believes retention has been reasonably solid recently. Given that engineer attrition is positioned as the largest downside risk, talent retention is a central management priority.

Over more than 20 years in business, management believes a virtuous cycle in which "talented people attract talented people" has been at work. The policy going forward is to further enhance the corporate brand, establish a growth trajectory, and continue recruiting top talent by communicating the company's appeal.

On incentive plans, the company operates standard employee programs but has nothing special in place; management intends to design new schemes going forward. No specific figures such as retention rates were disclosed.